Life Technologies says its tech is 100 times more potent; Synairgen to get Japanese patent for inhaled drugs;

> Life Technologies has developed new drug delivery technology for therapeutic applications that's 100 times more potent than previous formulations, the company says. Story

> Synairgen, based in the U.K., is expected to receive a Japanese patent for its inhaled interferon beta as a treatment for rhinovirus infections in asthma and COPD patients. Local delivery of IFN-beta to the lungs could limit the spread of virus to lungs. Item

> Euclid Systems will partner with Ora to conduct pre-clinical and clinical development of its collagen-based drug delivery system for treatment of glaucoma. Release

> Biopath Holdings, a biotechnology company developing a liposomal delivery technology for nucleic acid cancer drugs, is relocating its corporate headquarters to Houston. Announcement

> Advanced Injection Devices: Developments, Drivers and Directions for the Future. Report by Andy Fry, founder and director of Team Consulting in the UK. PDF of report

> So you want to use a carbon nanotube as a needle. The thing is, are they better for delivering injections or for collecting blood samples? Scientists find out. Release

Suggested Articles

The new digital Abilify is a breakthrough for Proteus Digital Health and its patient-tracking products, but not so much for Abilify's maker, Otsuka.

Adamis Pharmaceuticals' EpiPen contender Symjepi, which was rejected last year before the EpiPen havoc, won approval from the FDA.

Researchers in the U.K. have developed a technique to better predict results in liver cancer when drug-laden polymer beads are used to deliver medicines.